Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1573-4099
  • E-ISSN: 1875-6697

Abstract

Background

The purpose of this research is to develop an analytical method and validate it according to ICH guidelines for the estimation of Toremifene by RP-HPLC-PDA with molecular docking and ADMET analysis. From molecular docking, it came to know the receptor affinity specifically to estrogen receptors (ERα and ERβ), which are responsible for cancer therapy. ADMET analyses secure its therapeutic potential as well safety of the drug.

Methods

An isocratic method has developed by RP-HPLC-PDA (AGILENT 1100) with symmetry of 100 mm x 4.6 mm x 5 µm particle size C18 column and optimise mobile phase is methanol: 0.1% OPA (orthophosphoric acid) water ratio of 43:57% v/v. Under different conditions like acidic, alkaline, oxidative, and neutral environments, toremifene was tested for degradation.

Results

The developed method is validated in accordance with ICH guidelines. A calibration curve with an r2 value of 0.9987 has been prepared across the range of 10 to 50 µg/ml with five standard dilutions. The retention time of the drug is 5.575 minutes. The validation results are system suitability (%RSD-0.76), inter-day precision (%RSD 0.14-0.29), intraday precision (%RSD 0.08-0.34), accuracy (%RSD 0.16-0.96), and robustness (%RSD 0.16-0.35). In different intended conditions, four peaks are in 1 N HCl, two peaks in 1 N NaOH, three peaks in 10% HO (1hr), and one peak in neutral.

Conclusion

Toremifene, a Selective Estrogen Receptor Modulator (SERM), Drug pharmacokinetic properties and receptor binding affinity results are helpful in designing the analytical method. Developing the RP-HPLC-PDA method is found to be novel, simple and precise. It could be used for testing toremifene in bulk and pharmaceutical tablet dosage forms in quality control, as well as stability tests.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cad/10.2174/0115734099289409240307042531
2024-03-13
2025-10-17

  • From This Site

    /content/journals/cad/10.2174/0115734099289409240307042531
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MirK.B. AbrolV. WaniT.U. JanI. SinghN. KhanN.A. DarA.A. Sabri SultanR.M. LoneS.A. IesaM.A.M. AlhagS.K. Al-ShuraymL.A. HelmN. AL-FargaA. Validation and development of RP-HPLC method for quantification of glibenclamide in rat plasma and its application to pharmacokinetic studies in wistar rats.Heliyon2023911e2087610.1016/j.heliyon.2023.e2087637928045
     [Google Scholar]
  2. ShabirG.A. Development and validation of a reversed-phase HPLC method for the determination of hydroxybenzene in a cream formulation.Indian J. Pharm. Sci.201072330731110.4103/0250‑474X.7047521188038
     [Google Scholar]
  3. PereiraF.J. Rodríguez-CorderoA. LópezR. RoblesL.C. AllerA.J. Development and validation of an RP-HPLC-PDA method for determination of paracetamol, caffeine and tramadol hydrochloride in pharmaceutical formulations.Pharmaceuticals202114546610.3390/ph1405046634063393
     [Google Scholar]
  4. ChaudhariV.S. BorkarR.M. MurtyU.S. BanerjeeS. Analytical method development and validation of reverse-phase high-performance liquid chromatography (RP-HPLC) method for simultaneous quantifications of quercetin and piperine in dual-drug loaded nanostructured lipid carriers.J. Pharm. Biomed. Anal.202018611332510.1016/j.jpba.2020.11332532380356
     [Google Scholar]
  5. NikolinB. ImamovićB. VukM.S. SoberM. High performance liquid chromatography in pharmaceutical analyses.Bosn. J. Basic Med. Sci.2004425910.17305/bjbms.2004.340515629016
     [Google Scholar]
  6. SiddiquiM.R. AlOthmanZ.A. RahmanN. Analytical techniques in pharmaceutical analysis: A review.Arab. J. Chem.201710S1409S142110.1016/j.arabjc.2013.04.016
     [Google Scholar]
  7. SinghN. VayerP. TanwarS. PoyetJ.L. TsaiounK. VilloutreixB.O. Drug discovery and development: Introduction to the general public and patient groups.Fronti. Drug Discover.20233120141910.3389/fddsv.2023.1201419
     [Google Scholar]
  8. PaulD. SanapG. ShenoyS. KalyaneD. KaliaK. TekadeR.K. Artificial intelligence in drug discovery and development.Drug Discov. Today2021261809310.1016/j.drudis.2020.10.01033099022
     [Google Scholar]
  9. BurrowsJ.N. ElliottR.L. KanekoT. MowbrayC.E. WatersonD. The role of modern drug discovery in the fight against neglected and tropical diseases.MedChemComm20145668870010.1039/c4md00011k
     [Google Scholar]
  10. ChenJ. LuoX. QiuH. MackeyV. SunL. OuyangX. Drug discovery and drug marketing with the critical roles of modern administration.Am. J. Transl. Res.201810124302431230662672
     [Google Scholar]
  11. RamadanQ. PerinelliD.R. OrianL. BaratchiS. Editorial: Innovative approaches in drug discovery and development.Front. Med. Technol.20235120608810.3389/fmedt.2023.120608837251414
     [Google Scholar]
  12. ZhouS.F. ZhongW.Z. Drug design and discovery: Principles and applications.Molecules201722227910.3390/molecules2202027928208821
     [Google Scholar]
  13. XiaoX. MinJ.L. LinW.Z. LiuZ. ChengX. ChouK.C. iDrug-Target: Predicting the interactions between drug compounds and target proteins in cellular networking via benchmark dataset optimization approach.J. Biomol. Struct. Dyn.201533102221223310.1080/07391102.2014.99871025513722
     [Google Scholar]
  14. PatelH.K. BihaniT. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.Pharmacol. Ther.201818612410.1016/j.pharmthera.2017.12.01229289555
     [Google Scholar]
  15. ZhaoL. ZhouS. GustafssonJ.Å. Nuclear receptors: Recent drug discovery for cancer therapies.Endocr. Rev.20194051207124910.1210/er.2018‑0022230869771
     [Google Scholar]
  16. PengJ. SenguptaS. JordanV.C. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.Anticancer. Agents Med. Chem.20099548149910.2174/18715200978845183319519291
     [Google Scholar]
  17. MartinkovichS. ShahD. PlaneyS.L. ArnottJ.A. Selective estrogen receptor modulators: Tissue specificity and clinical utility.Clin. Interv. Aging201491437145225210448
     [Google Scholar]
  18. AnK.C. Selective estrogen receptor modulators.Asian Spine J.201610478779110.4184/asj.2016.10.4.78727559463
     [Google Scholar]
  19. JefferiN.E.S. ShamhariA.A. AzharN.N.K.Z. ShinJ.G.Y. KharirN.A.M. AzharM.A. HamidZ.A. BudinS.B. TaibI.S. The role of ERα and ERβ in castration-resistant prostate cancer and current therapeutic approaches.Biomedicines202311382610.3390/biomedicines1103082636979805
     [Google Scholar]
  20. ZhangJ.Y. ZhongY.H. ChenL.M. ZhuoX.L. ZhaoL.J. WangY.T. Recent advance of small-molecule drugs for clinical treatment of osteoporosis: A review.Eur. J. Med. Chem.202325911565410.1016/j.ejmech.2023.11565437467618
     [Google Scholar]
  21. SmithM.R. MalkowiczS.B. ChuF. ForrestJ. PriceD. SieberP. BarnetteK.G. RodriguezD. SteinerM.S. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study.J. Urol.2008179115215510.1016/j.juro.2007.08.13718001802
     [Google Scholar]
  22. PaterniI. GranchiC. KatzenellenbogenJ.A. MinutoloF. Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential.Steroids201490132910.1016/j.steroids.2014.06.01224971815
     [Google Scholar]
  23. LumachiF. SanteufemiaD.A. BassoS.M. Current medical treatment of estrogen receptor-positive breast cancer.World J. Biol. Chem.20156323123910.4331/wjbc.v6.i3.23126322178
     [Google Scholar]
  24. ClusanL. FerrièreF. FlouriotG. PakdelF. A basic review on estrogen receptor signaling pathways in breast cancer.Int. J. Mol. Sci.2023247683410.3390/ijms2407683437047814
     [Google Scholar]
  25. HeldringN. PikeA. AnderssonS. MatthewsJ. ChengG. HartmanJ. TujagueM. StrömA. TreuterE. WarnerM. GustafssonJ.Å. Estrogen receptors: How do they signal and what are their targets.Physiol. Rev.200787390593110.1152/physrev.00026.200617615392
     [Google Scholar]
  26. EllemS.J. RisbridgerG.P. The dual, opposing roles of estrogen in the prostate.Ann. N. Y. Acad. Sci.20091155117418610.1111/j.1749‑6632.2009.04360.x19250203
     [Google Scholar]
  27. FujimuraT. TakahashiS. KumeH. UranoT. TakayamaK. YamadaY. SuzukiM. FukuharaH. NakagawaT. InoueS. HommaY. Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: A randomized controlled phase II a trial.BMC Cancer201515183610.1186/s12885‑015‑1871‑z26526623
     [Google Scholar]
  28. SongD. HuY. DiaoB. MiaoR. ZhangB. CaiY. ZengH. ZhangY. HuX. Effects of tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast cancer.BMC Cancer202121179810.1186/s12885‑021‑08538‑534246237
     [Google Scholar]
  29. VogelC.L. JohnstonM.A. CapersC. BracciaD. Toremifene for breast cancer: A review of 20 years of data.Clin. Breast Cancer20141411910.1016/j.clbc.2013.10.01424439786
     [Google Scholar]
  30. MaggioR.M. VignaduzzoS.E. KaufmanT.S. Practical and regulatory considerations for stability-indicating methods for the assay of bulk drugs and drug formulations.Trends Analyt. Chem.201349577010.1016/j.trac.2013.05.008
     [Google Scholar]
  31. RoyA. HenryJ. WilkenA. MalaveC.L. Current practices and considerations for a stability-indicating method in pharmaceutical analysis.LC GC N. Am.2014328568575
     [Google Scholar]
  32. BlessyM. PatelR.D. PrajapatiP.N. AgrawalY.K. Development of forced degradation and stability indicating studies of drugs—A review.J. Pharm. Anal.20144315916510.1016/j.jpha.2013.09.00329403878
     [Google Scholar]
  33. AmmannC. Stability studies needed to define the handling and transport conditions of sensitive pharmaceutical or biotechnological products.AAPS PharmSciTech20111241264127510.1208/s12249‑011‑9684‑021948319
     [Google Scholar]
  34. YadavP. TaleuzzamanM. KumarP. Simultaneous estimation of aspirin, atorvastatin calcium and clopidogrel bisulphate in a combined dosage form by RP-HPLC.Asian J. Chem. Sci.20196411010.9734/ajocs/2019/v6i419003
     [Google Scholar]
  35. VermaD. MirzaM.A. TaleuzzamanM. KhurooT. TalegaonkarS. KumarR. SahuP.L. IqbalZ. Development and validation of RP-HPLC method to simultaneously detect lactone and carboxylate form of Topotecan along with Thymoquinone: Application to nanoparticulate anticancer formulation system.J. Anal. Chem.2020450350910.1134/S1061934820040152
     [Google Scholar]
  36. JahanM.S. IslamM.J. BegumR. KayeshR. RahmanA. A study of method development, validation, and forced degradation for simultaneous quantification of paracetamol and ibuprofen in pharmaceutical dosage form by RP-HPLC method.Anal. Chem. Insights20149758125452691
     [Google Scholar]
  37. PeramanR. LalithaK.V. RajaN.M. RouthuH.B. Identification of degradation products and stability-indicating RP-HPLC method for determination of flupirtine maleate in pharmaceutical dosage forms.Sci. Pharm.201482228129310.3797/scipharm.1310‑0124959399
     [Google Scholar]
  38. de JuniorR.A.B. CarneiroL.R. Chemometrics approaches in forced degradation studies of pharmaceutical drugs.Molecules20192420380410.3390/molecules2420380431652589
     [Google Scholar]
  39. ICH guidelines on Stability Testing of New Drug Substances and Products. 2003. ICH - Q1A (R2).Available from:https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf 2003
  40. Pawul-GrubaM. KiljanekT. MadejskaA. OsekJ. Development of a high performance liquid chromatography with diode array detector (HPLC-DAD) method for determination of biogenic amines in ripened cheeses.Molecules20222723819410.3390/molecules2723819436500285
     [Google Scholar]
  41. JainD. BasniwalP.K. Forced degradation and impurity profiling: Recent trends in analytical perspectives.J. Pharm. Biomed. Anal.201386113510.1016/j.jpba.2013.07.01323969330
     [Google Scholar]
  42. Nageswara RaoR. NagarajuV. An overview of the recent trends in development of HPLC methods for determination of impurities in drugs.J. Pharm. Biomed. Anal.200333333537710.1016/S0731‑7085(03)00293‑014550856
     [Google Scholar]
  43. HolmR. ElderD.P. Analytical advances in pharmaceutical impurity profiling.Eur. J. Pharm. Sci.20168711813510.1016/j.ejps.2015.12.00726690047
     [Google Scholar]
  44. GómezC. PozoO.J. DiazR. SanchoJ.V. VilarocaE. SalvadorJ.P. MarcoM.P. HernandezF. SeguraJ. VenturaR. Mass spectrometric characterization of urinary toremifene metabolites for doping control analyses.J. Chromatogr. A20111218294727473710.1016/j.chroma.2011.05.07321683367
     [Google Scholar]
  45. SalvadorJ.P. Vila-RocaE. MonfortN. VenturaR. MarcoM.P. New approach based on immunochemical techniques for monitoring of selective estrogen receptor modulators (SERMs) in human urine.J. Pharm. Biomed. Anal.201815614715210.1016/j.jpba.2018.04.02729704771
     [Google Scholar]
  46. LiX. ZhaoJ. XuR. PanL. LiuY.M. Mass spectrometric quantification of microRNAs in biological samples based on multistage signal amplification.Analyst202014551783178810.1039/C9AN02064K31942587
     [Google Scholar]
  47. LiuX. ZhangJ. YinJ. DuanH. WuY. ShaoB. Analysis of hormone antagonists in clinical and municipal wastewater by isotopic dilution liquid chromatography tandem mass spectrometry.Anal. Bioanal. Chem.201039682977298510.1007/s00216‑010‑3531‑020195582
     [Google Scholar]
  48. MazzarinoM. de la TorreX. FiaccoI. PalermoA. BotrèF. Drug‐drug interaction and doping, part 1: An in vitro study on the effect of non‐prohibited drugs on the phase I metabolic profile of toremifene.Drug Test. Anal.20146548249110.1002/dta.159224431005
     [Google Scholar]
  49. XiaoS. YangY. ZhangJ. WuY. ShaoB. Determination of 6 antiestrogens in fish tissues by ultra performance liquid chromatography-tandem mass spectrometry.Se Pu201129111055106122393691
     [Google Scholar]
  50. TaleuzzamanM. AliS. GilaniS.J. ImamS.S. HafeezA. Ultra performance liquid chromatography (UPLC)-a review.Austin J. Anal. Pharm. Chem.2015261056
     [Google Scholar]
  51. ReddyS.P. BabuS.K. KumarN. Development and validation of a stability-indicating RP-HPLC method for the simultaneous estimation of process related impurities and degradation products of rasagiline mesylate in pharmaceutical formulation.J. Chromatogr. Sci.201351324224910.1093/chromsci/bms13422988002
     [Google Scholar]
  52. ShabirG.A. John LoughW. ArainS.A. BradshawT.K. Evaluation and application of best practice in analytical method validation.J. Liq. Chromatogr. Relat. Technol.200730331133310.1080/10826070601084753
     [Google Scholar]
  53. LohmannW. KarstU. Electrochemistry meets enzymes: Instrumental on-line simulation of oxidative and conjugative metabolism reactions of toremifene.Anal. Bioanal. Chem.200939451341134810.1007/s00216‑008‑2586‑719139854
     [Google Scholar]
  54. KalalD.J. RedasaniV.K. Stability-indicating RP-HPLC method development and validation for estimation of Mupirocin calcium in bulk and in pharmaceutical formulation.Future J. Pharm. Sci.2022812110.1186/s43094‑022‑00412‑w
     [Google Scholar]
  55. Validation of analytical procedures: Text and methodology Q2(R1).Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf 2005
  56. ICHDraft Revised Guidance on Q1A (R) Stability Resting of New Drug Substances and Products.Fed. Regist.20006521446
     [Google Scholar]
  57. FDACDER, Beers, and Donald, Analytical Procedures and Methods Validation for Drugs and Biologics Guidance for IndustrySilver Spring, MD, USAFDA2015
     [Google Scholar]
  58. AleemH. ZhaoY. LordS. McCarthyT. SharrattP. Pharmaceutical process validation: An overview.Proc. Inst. Mech. Eng., E J. Process Mech. Eng.2003217214115110.1243/095440803766612801
     [Google Scholar]
  59. KailaH.O. AmbasanaM.A. ThakkarR.S. SaravaiaH.T. ShahA.K. A new improved RP-HPLC method for assay of rosuvastatin calcium in tablets.Indian J. Pharm. Sci.201072559259810.4103/0250‑474X.7852621694991
     [Google Scholar]
  60. PatilR. AhmedA.K.L. FirkeS. PawarD. RP-HPLC PDA analysis of tranexamic acid in bulk and tablet dosage form.Anal. Chem. Lett.20177681382110.1080/22297928.2017.1422438
     [Google Scholar]
  61. AlquadeibB.T. Development and validation of a new HPLC analytical method for the determination of diclofenac in tablets.Saudi Pharm. J.2019271667010.1016/j.jsps.2018.07.02030662308
     [Google Scholar]
  62. AliS. TaleuzzamanM. GilaniS.J. AhmedM.L. HafeezA. Quantitative estimation of Donepenzil hydrochloride tablet by HPLC.Int. J. Pharm. Chem.2016626266
     [Google Scholar]
  63. MittalA. ParmarS. GilaniS.J. ImamS.S. TaleuzzamanM. Optimization and validation for simultaneous estimation of citicoline and piracetam in bulk and tablet formulations using RP-HPLC method: Analytical quality by design approach.Asian J. Res. Chem201710219810.5958/0974‑4150.2017.00034.7
     [Google Scholar]
  64. Al-HawashL.A. ShakyaA.K. SaleemM.L. Stability-indicating HPLC determination of trandolapril in bulk drug and pharmaceutical dosage forms.Int. J. Anal. Chem.201520151810.1155/2015/82051725802524
     [Google Scholar]
  65. DongalaT. KatariN.K. PalakurthiA.K. JonnalagaddaS.B. Development and validation of a generic RP‐HPLC PDA method for the simultaneous separation and quantification of active ingredients in cold and cough medicines.Biomed. Chromatogr.20193311e464110.1002/bmc.464131265736
     [Google Scholar]
  66. RossiR.C. MouraJ.G.L. MossmannV. WeimerP. FröehlichP.E. A new, rapid and simple RP-HPLC method for stability quantification of a protease inhibitor in tablets.J. Chromatogr. Sci.202260767167710.1093/chromsci/bmab10934522954
     [Google Scholar]
  67. SaeedM.A. AnsariM.T. ChB.A. ZamanM. RP-HPLC method for the determination and quantification of artesunate.J. Chromatogr. Sci.202058869569910.1093/chromsci/bmaa03732719858
     [Google Scholar]
  68. PatelJ.K. PatelN.K. Stability-indicating RP-HPLC method for the determination of ambrisentan and tadalafil in pharmaceutical dosage form.Sci. Pharm.201482474976310.3797/scipharm.1403‑2226279975
     [Google Scholar]
  69. MengX.Y. ZhangH.X. MezeiM. CuiM. Molecular docking: A powerful approach for structure-based drug discovery.Curr. Computeraided Drug Des.20117214615710.2174/15734091179567760221534921
     [Google Scholar]
  70. Méndez-ÁlvarezD. Torres-RojasM.F. Lara-RamirezE.E. MarchatL.A. RiveraG. Ligand-based virtual screening, molecular docking, and molecular dynamic simulations of new β-estrogen receptor activators with potential for pharmacological obesity treatment.Molecules20232811438910.3390/molecules2811438937298864
     [Google Scholar]
  71. KharatC ShirsatVA KodguleYM KodguleM A validated RP-HPLC stability method for the estimation of chlorthalidone and its process-related impurities in an API and tablet formulation.Int J Anal Chem20202020359380510.1155/2020/3593805
     [Google Scholar]
  72. JadhavS.D. ButleS.R. PatilS.D. JagtapP.K. Validated stability indicating RP-HPLC method for simultaneous determination and in vitro dissolution studies of thiocolchicoside and diclofenac potassium from tablet dosage form.Arab. J. Chem.20158111812810.1016/j.arabjc.2011.01.018
     [Google Scholar]
/content/journals/cad/10.2174/0115734099289409240307042531
Loading
Molecular Docking and ADMET Analysis Strategy-based Stability Indicating RP-HPLC-PDA Method Development and Validation of Toremifene
Curr. Computeraided Drug Des. 21, 680 (2025); https://doi.org/10.2174/0115734099289409240307042531
/content/journals/cad/10.2174/0115734099289409240307042531
/content/journals/cad/10.2174/0115734099289409240307042531
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): ADMET analysis; API; estrogen receptors; forced degradation; ICH guidelines; Molecular docking; RP-HPLC

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test